Back to Search Start Over

Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer.

Authors :
Tariq M
Hussain N
Rehman K
Akash MSH
Al Haddad AHI
Said ASA
Fatease AA
Alamri A
Safhi AY
Sabei FY
Awadh AAA
Hussain M
Source :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 May; Vol. 161, pp. 114527. Date of Electronic Publication: 2023 Mar 15.
Publication Year :
2023

Abstract

M2 polarized tumor-associated macrophages (TAMs) have a multifunctional role in cancer initiation, progression, metastasis, and contribute to chemotherapeutic resistance. Therefore, identifying M2 polarized TAMs is a potential target for cancer therapeutic intervention. The underlying mechanism that target the TAMs M2 polarized macrophages remains primarily uncharacterized; however, only a few compounds have been identified that inhibit TAMs M2 polarized macrophages. In this research, we investigated that lapatinib could effectively suppress the expression of IL <superscript>_</superscript> 13-induced M2 polarized macrophages surface markers i.e., CD163 and CD206, and downregulation of M2 genes such as Fizz1, Mrc1, Arg1, IL-10, Ym1, nd CCL2 in vitro. Moreover, lapatinib abrogated the M2 polarized macrophage-mediated cancer cells invasion and migration. Mechanistically, in our study, lapatinib inhibited IL-13 triggered STAT6 phosphorylation. Furthermore, in LLCs tumor model, lapatinib significantly reduced tumorigenesis, followed by the downregulation of percentages of M2 marker CD206 <superscript>+</superscript> and CD68 <superscript>+</superscript> in the tumor. This downregulation correlates with chemopreventive effect of lapatinib. All taken together, these results demonstrated that lapatinib effectively prevents the macrophage M2 polarization and indicates a potential mechanism for preventing the tumor growth via M2 polarized polarization intervention.<br />Competing Interests: Conflict of interest statement No conflict of interest.<br /> (Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)

Details

Language :
English
ISSN :
1950-6007
Volume :
161
Database :
MEDLINE
Journal :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Publication Type :
Academic Journal
Accession number :
36931028
Full Text :
https://doi.org/10.1016/j.biopha.2023.114527